Zoetis (ZTS) Aandelenoverzicht
Zoetis Inc. houdt zich bezig met het ontdekken, ontwikkelen, produceren en op de markt brengen van geneesmiddelen, vaccins, diagnostische producten en diensten, biologische hulpmiddelen, genetische tests en precisieoplossingen voor diergezondheid voor de diergezondheidsindustrie in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 5/6 |
Beloningen
Risicoanalyse
ZTS Community Fair Values
Create NarrativeSee what 198 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$92.92
FV
11.5% ondergewaardeerd intrinsieke korting4.06%
Revenue growth p.a.
164
users have viewed this narrative4users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Zoetis Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$82.20 |
| 52 Week Hoogtepunt | US$168.83 |
| 52 Week Laag | US$72.38 |
| Bèta | 0.74 |
| 1 maand verandering | -0.76% |
| 3 maanden verandering | -31.38% |
| 1 Jaar Verandering | -50.81% |
| 3 jaar verandering | -50.48% |
| 5 jaar verandering | -55.73% |
| Verandering sinds IPO | 165.08% |
Recent nieuws en updates
Seeking Alpha • Jun 02
Zoetis: Potential Deep Value Play With 60%+ Upside Potential Dividend Investors Should Watch
Summary Zoetis has dropped over 50% in the past year, creating a potentially attractive entry for long-term dividend growth investors. ZTS's underperformance stems from persistent inflation, lower U.S. companion animal demand, and increased competition, leading to revised 2026 guidance and a recent sell-off. Despite headwinds, ZTS maintains a strong balance sheet, well-covered dividend (39% payout ratio), and ongoing buybacks, supporting long-term shareholder value. With a forward P/E of 11.5x—well below peers and historical averages—ZTS offers over 60% upside, but macro risks and near-term pressures warrant a hold rating. Read the full article on Seeking Alpha
Narratiefupdate • May 26
ZTS: Premium Pet Health Portfolio Will Support Reset Earnings Path Forward
Zoetis' analyst fair value estimate has been reset from $151.00 to about $124.59 as analysts trim price targets after a difficult Q1, rising competitive pressures, and signs that premium pricing is meeting more cautious consumer demand, despite longer term guidance implying improvement. Analyst Commentary Recent research points to a reset in expectations for Zoetis, with target prices broadly trimmed as analysts rework their models around the latest Q1 update, rising competition, and more cautious consumer behavior toward premium products.
Nieuw narratief • May 26
Zoetis down -50% over the past year
World's leading animal pharma company at 13x PE with 9% EPS growth Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock.Recent updates
Seeking Alpha • Jun 02
Zoetis: Potential Deep Value Play With 60%+ Upside Potential Dividend Investors Should Watch
Summary Zoetis has dropped over 50% in the past year, creating a potentially attractive entry for long-term dividend growth investors. ZTS's underperformance stems from persistent inflation, lower U.S. companion animal demand, and increased competition, leading to revised 2026 guidance and a recent sell-off. Despite headwinds, ZTS maintains a strong balance sheet, well-covered dividend (39% payout ratio), and ongoing buybacks, supporting long-term shareholder value. With a forward P/E of 11.5x—well below peers and historical averages—ZTS offers over 60% upside, but macro risks and near-term pressures warrant a hold rating. Read the full article on Seeking AlphaNarratiefupdate • May 26
ZTS: Premium Pet Health Portfolio Will Support Reset Earnings Path Forward
Zoetis' analyst fair value estimate has been reset from $151.00 to about $124.59 as analysts trim price targets after a difficult Q1, rising competitive pressures, and signs that premium pricing is meeting more cautious consumer demand, despite longer term guidance implying improvement. Analyst Commentary Recent research points to a reset in expectations for Zoetis, with target prices broadly trimmed as analysts rework their models around the latest Q1 update, rising competition, and more cautious consumer behavior toward premium products.Nieuw narratief • May 26
Zoetis down -50% over the past year
World's leading animal pharma company at 13x PE with 9% EPS growth Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock.
Narratiefupdate • May 03
ZTS: Share Repurchases And Capital Discipline Will Support Medium-Term Upside
Analysts have modestly trimmed their Zoetis fair value estimate by about $3 to $184, reflecting mixed updates to revenue growth, margins, and long term P/E assumptions after recent shifts in price targets and ratings across the Street. Analyst Commentary Recent research updates on Zoetis reflect a mix of reduced price targets, a downgrade on growth concerns, and fresh bullish coverage.
Narratiefupdate • Apr 19
ZTS: Fair View Weighs Organic Growth Concerns Against Pipeline Execution Risk
Analysts have trimmed the Zoetis fair value estimate by $3 to $127, reflecting a mix of cautious views around organic growth and slightly adjusted assumptions for future P/E, revenue growth, and profitability, even as some firms maintain a bullish stance on the stock. Analyst Commentary Recent Street research around Zoetis shows a split tape, with several bearish analysts focusing on weaker organic growth trends and execution risk, even as others remain constructive on the long term story.Narratiefupdate • Apr 04
ZTS: Share Repurchases And Execution Recovery Will Support Medium-Term Upside
Analyst targets on Zoetis have shifted modestly, with a small net reduction in the Street price target in dollar terms as some analysts cite concerns about organic growth and an innovation "air pocket," even as others make minor upward adjustments. Analyst Commentary Recent Street research on Zoetis reflects a split view, with some analysts emphasizing concerns around organic growth and an innovation air pocket, while others are adjusting targets in a more constructive way.Narratiefupdate • Mar 21
ZTS: Future OA Pain Launch And Buybacks Will Support Medium-Term Upside
Narrative Update The updated analyst price target for Zoetis moves from about $197.51 to $187.59, reflecting analysts' mixed views. Some cite softer organic growth and an innovation "air pocket," while others make smaller price target adjustments.Narratiefupdate • Mar 06
ZTS: Fair View Balances Growth Concerns With Innovation Air Pocket Risk
Zoetis's analyst price target holds steady at $130, as analysts balance concerns about organic growth and an innovation "air pocket" with stable margin expectations and a lower future P/E assumption. Analyst Commentary Recent Street research on Zoetis points to a more cautious tone, with several bearish analysts questioning the near term growth setup and how that lines up with the current valuation.Narratiefupdate • Feb 20
ZTS: Future Pet Osteoarthritis Pipeline Will Support Premium Multiple Potential
Zoetis' analyst fair value estimate has been reset from $158.22 to $151.00, as analysts balance recent price target changes and a slightly lower assumed future P/E multiple against broadly steady growth and margin assumptions. Analyst Commentary Recent Street research on Zoetis points to a mixed setup, with some analysts seeing support for the current valuation and others focusing on execution risk and the product pipeline.Narratiefupdate • Feb 06
ZTS: Future OA Pain Launch Execution Will Drive Medium-Term Upside Potential
Analysts have trimmed their Zoetis fair value estimate from about US$200 to roughly US$197.51. This reflects recent price target cuts and more cautious views around product launch headwinds and competition, even as they still see solid margins and a premium P/E as part of the story.Narratiefupdate • Jan 22
ZTS: Fair Outlook Balances OA Pain Headwinds With New Antibody Approvals
Narrative update on Zoetis The analyst fair value estimate for Zoetis has been reset from US$153 to US$130 as analysts factor in slower expected revenue growth, a slightly higher discount rate, lower assumed future P/E multiples, and ongoing competitive and product launch headwinds highlighted in recent research. Analyst Commentary Recent research on Zoetis has tilted more cautious, with several bearish analysts resetting expectations around growth, execution, and what investors are willing to pay for the stock.Narratiefupdate • Jan 08
ZTS: Future Product Launches Will Offset Current Competition Pressures
Analysts have trimmed their price targets on Zoetis, reflecting a fair value move from about $170 to $158 as they factor in product launch headwinds, tougher competition in key franchises, and more cautious revenue expectations for 2025 and 2026. Analyst Commentary Recent Street research reflects a mixed but more cautious stance on Zoetis, with several firms trimming price targets and reassessing growth and competitive risks over the next few years.Narratiefupdate • Dec 15
ZTS: Execution In Animal Health Leadership Will Drive Medium-Term Upside Potential
Analysts have cut their fair value estimate for Zoetis by about $30,000,000,000 to roughly $200,000,000,000, reflecting expectations for slower mid decade revenue growth, modestly lower margins, and a less generous future earnings multiple amid increasing competitive and product launch headwinds. Analyst Commentary Recent Street research reflects a more balanced stance on Zoetis, with fair value expectations reset lower but many firms still highlighting the company as a structural leader in animal health.Narratiefupdate • Nov 30
ZTS: Earnings Will Recover As Competition Pressures Recent Product Launches
Zoetis's fair value target experienced a modest reduction to $169.96. Analysts highlighted competitive pressures and headwinds from recent product launches as key drivers for the change.Narratiefupdate • Nov 16
ZTS: Earnings Will Rebound As Volume Pressures Ease In 2026
Zoetis' analyst price target has been reduced from approximately $188 to $171 per share, as analysts cite tempered growth expectations and revised financial assumptions following recent quarterly updates. Analyst Commentary Following Zoetis' latest quarterly updates and subsequent guidance revision, analysts have updated their perspectives on the company's outlook.Narratiefupdate • Nov 01
ZTS: Global Demand Trends Will Drive Earnings Consistency In Coming Quarters
Narrative Update: Zoetis Analyst Price Target Adjustment Analysts have modestly decreased their price target for Zoetis from $165 to $158, citing a more cautious outlook ahead of upcoming results. Analyst Commentary Analyst perspectives on Zoetis highlight both optimism regarding the company’s long-term fundamentals as well as heightened caution leading into upcoming earnings releases.Narratiefupdate • Oct 18
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $189.22 to $188.83, citing modest revisions to revenue growth estimates. They also noted a marginal increase in expected profit margins.Narratiefupdate • Oct 04
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $190.29 to $189.22, citing marginally softer revenue growth and profit margin expectations. What's in the News Zoetis received conditional FDA approval for Dectomax-CA1, the first and only injectable for preventing and treating infestations caused by New World screwworm larvae in cattle.Analyseartikel • Jun 30
Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Mar 25
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Summary Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company. Despite the disappointing guidance for FY 2025 and the threat of possible competition, there are still plenty of growth opportunities in existing and untapped markets. Based on the earnings growth model, ZTS looks reasonably priced. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Zoetis: Focusing On The High Margin Segments
Summary The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients. I rate Zoetis as a buy, expecting a 10.3% investment rate of return, but I favor IDEXX for my portfolio. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Summary Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share. The company's diversified product portfolio and international presence position it well for sustained growth, particularly in the expanding pet care market. Read the full article on Seeking AlphaSeeking Alpha • Dec 26
The Wall Street Journal Vs. Zoetis
Summary The Wall Street Journal released an article claiming that Zoetis' OA pain drug (Librela) is not safe. I go over these claims and explain why I believe they are unfounded. Librela might face a label change soon, but I don't think there's any reason to worry. I explain why. Read the full article on Seeking AlphaSeeking Alpha • Dec 06
Zoetis: Are Competition And Price Increases A Cause For Concern?
Summary Zoetis is the market leader in a growing industry, and the numbers are starting to show its dominance. The company reported a very strong Q3 thanks to several growth drivers. Are competition and price increases a cause for concern? We discuss this in the article. Read the full article on Seeking AlphaSeeking Alpha • Nov 29
Zoetis: Healing Paws, Growing Profits
Summary Zoetis is active in multiple segments that are all expected to grow at a CAGR of 4% or more. The company has growing revenues, a strong balance sheet, a high FCF margin, and no major maturities. Librela, Solensia and Simparica Trio will drive the stock going forward. I estimate shares to be undervalued by approximately 16%. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
Summary Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending, making its revenues less susceptible to economic downturns. Zoetis boasts a strong competitive moat with a diverse product portfolio, significant patent protection, and consistent R&D investment. Despite trading at a premium, Zoetis' stable growth, robust market position, and low-risk profile make it a compelling long-term investment. Read the full article on Seeking AlphaSeeking Alpha • Oct 09
Zoetis: A Solid Choice For The Young Dividend Growth Investor
Summary Zoetis excels in innovation, creating new categories and consistently raising the standard of care, outperforming competitors with strong execution. Disciplined capital allocation is evident with strategic exits and reinvestments in high-return growth areas, ensuring sustained business growth. Their market leadership, potential growth opportunities, and dividend metrics make ZTS a suitable candidate for the young dividend growth investor. Based on DCF analysis, ZTS is currently reasonably priced for investors with a long time horizon. Read the full article on Seeking AlphaSeeking Alpha • Sep 26
Zoetis: Investing In Pet Health And Portfolio Wealth
Summary Zoetis, a leader in veterinary healthcare, has consistently outperformed the market with robust revenue growth and strong margins, even during industry challenges. The company’s innovation, focus on companion animals, and strategic divestitures position it well for continued growth, despite prior concerns over drug risks. With a modest dividend yield, Zoetis remains a solid investment for dividend growth, backed by a $6 billion buyback program and long-term market potential. Read the full article on Seeking AlphaRendement voor aandeelhouders
| ZTS | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 7.6% | 5.6% | -3.3% |
| 1Y | -50.8% | 37.6% | 22.3% |
Rendement versus industrie: ZTS presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 37.6 % opleverde.
Rendement versus markt: ZTS presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 22.3 % opleverde.
Prijsvolatiliteit
| ZTS volatility | |
|---|---|
| ZTS Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: ZTS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van ZTS is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2012 | 14,500 | Kristin Peck | www.zoetis.com |
Zoetis Inc. houdt zich bezig met het ontdekken, ontwikkelen, produceren en verkopen van medicijnen, vaccins, diagnostische producten en diensten, biologische hulpmiddelen, genetische tests en precisieoplossingen voor diergezondheid voor de diergezondheidsindustrie in de Verenigde Staten en internationaal. Het bedrijf verkoopt voornamelijk producten voor gezelschapsdieren, waaronder honden, katten en paarden, en diersoorten, waaronder vee, zoals runderen, varkens, pluimvee, vissen en schapen. Het bedrijf biedt ook parasiticiden, vaccins, dermatologie, anti-infectiva, pijn en sedatie, andere farmaceutische middelen en diergezondheidsdiagnostiek.
Zoetis Inc. Samenvatting
| ZTS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$33.04b |
| Inkomsten(TTM) | US$2.67b |
| Inkomsten(TTM) | US$9.53b |
12.9x
Koers/Winstverhouding3.6x
P/S-verhoudingIs ZTS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ZTS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$9.53b |
| Kosten van inkomsten | US$2.68b |
| Brutowinst | US$6.85b |
| Overige uitgaven | US$4.18b |
| Inkomsten | US$2.67b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 6.37 |
| Brutomarge | 71.84% |
| Nettowinstmarge | 28.03% |
| Schuld/Eigen Vermogen Verhouding | 280.3% |
Hoe presteerde ZTS op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
2.6%
Huidig dividendrendement33%
UitbetalingsratioBetaalt ZTS een betrouwbaar dividend?
Zie ZTS dividendgeschiedenis en benchmarks| Zoetis dividenddata | |
|---|---|
| Ex Dividend Datum | Jul 20 2026 |
| Betaaldatum dividend | Sep 01 2026 |
| Dagen tot Ex-dividend | 39 days |
| Dagen tot dividendbetaaldatum | 82 days |
Betaalt ZTS een betrouwbaar dividend?
Zie ZTS dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/09 12:28 |
| Aandelenkoers aan het einde van de dag | 2026/06/09 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Zoetis Inc. wordt gevolgd door 40 analisten. 18 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Charles Butler | Barclays |
| Glen Santangelo | Barclays |